+ Watch CAH
on My Watchlist
The Company is a provider of products and services that improve the safety and productivity of healthcare.
Positive: - Defensive blue chip - Good long-term uptrend with low vola - Obamacare driven health spending expansion gives them a lot of tailwind Negative: - Expensive, but this can be safely ignored in this FED driven market Strategy: BVn
Should benefit from the expansion of health services since this is a play based on volumes.
Dividends500 tracks the 200 strongest dividends in the S&P 500. To qualify as a strong dividend, the company must meet two simple requirements:- A payout ratio below 50%- An increasing dividend from the prior yearBecause there are more than 200 dividend paying companies in the S&P 500 that meet these requirements, the qualifying companies with the largest dividend yields were chosen. Dividends500 intends to test this FactSet article, which highlights these strong dividend paying companies and their outperformance versus the S&P 500 as a whole (Page 12).http://www.factset.com/websitefiles/PDFs/dividend/dividend_12.16.13If you have questions or see something you think is inaccurate feel free to let me know.
Strong Healthcare company with decent dividend set to profit from an aging population.
Consistent dividend increases and capital opportunities from partnership with CVS/Caremark
Div. (Yield) $1.21 (1.8%)Current Yield . . . . . . .3.18%
Industry trends counter to distributor model. Lost WAG and Express Scripts contracts.
Great P/E and P/S, 2% dividend yield. Strong company with a strong future ahead.
Betting on an Ohio company that's also a leader in the medical industry. Cardinal should be well-positioned regardless of what happens to Washington's push for socialized medicine.
Dividend will keep this solid.
4/12 screen #2: percentile and CSspeculating with new screen, high analyst opinion
A winner from the health care reform
This is not a screaming deal but with the dividend factored in it looks like they should be priced between $42 and $50. EPS growth is around 3.5% for the past 8 years (with moderate variance), revenue growth is more consistent and around 9.5%.Their net margin is low, debt is average, return on assets is high. They compete directly with AmerisourceBergen and McKesson; all three seem to be quality companies with similar performance potential.
Recession proof niche.
Long term buy
New filibuster-proof Congress should reduce the risk of any sweeping health care changes in the near future. Their focus on growing generics would help them remain competitive regardless. Solid ROE, good work being done to increase focus on core competancies, and pharmaceuticals should continue to have recession- and inflation-resistant demand.
i have bought in at 27.90 and profited from this one.good company a benjamin graham pick. its currently at 12p/e and still a bargain.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions